Drug Profile
Research programme: adoptive T-cell therapy - Medigene
Alternative Names: Immunotherapy-Medigene Immunotherapies; TCR-modified T-cells-Medigene Immunotherapies; TCR-transgenic T-cells - Medigene ImmunotherapiesLatest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Helmholtz Zentrum Munchen; Max Delbruck Center for Molecular Medicine
- Developer Medigene Immunotherapies
- Class Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for preclinical development in Cancer in Germany (Parenteral)
- 02 May 2019 Pharmacodynamics data from a preclinical trial in cancer released by Medigene
- 02 Apr 2019 Interim data from preclinical studies in cancer presented at the American Association for Cancer Research Annual Meeting (AACR-2019)